Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
In the Literature
Adverse Events Reporting Suboptimal in Oncology Publications
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
Transparent and comprehensive reporting of AEs in published results of oncology-related clinical trials is crucial for the treatment of patients with cancer. In efforts to improve reporting of clinical trials results, the Consolidated Standards of Reporting Trials (CONSORT) extension group developed 10 recommendations in 2003 for reporting AEs. A new study of 175 publications assessed the degree to which the publication of phase 3 trials in oncology adhered with CONSORT recommendations (Sivendran S, et al.
J Clin Oncol
. 2014;32:83-89).
Read Article
Obinutuzumab Outperforms Rituximab in Older Patients with CLL
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
The anti-CD20 antibody rituximab (Rituxan), combined with chemotherapy agents, had been shown to prolong overall survival (OS) in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL), but not in those with comorbidities.
Read Article
Long-Term Cetuximab Therapy Shows Early Tumor Shrinkage in Colorectal Cancer
In the Literature
November 2013, Vol 4, No 9
In a new study, researchers analyzed data from 2 trials to determine if early tumor shrinkage was associated with long-term outcomes in patients with colorectal cancer receiving first-line treatment with cetuximab (Piessevaux H, et al.
J Clin Oncol
. 2013;31:3764-3775).
Read Article
Gemcitabine Increases Survival for Patients with Resected Pancreatic Cancer
In the Literature
November 2013, Vol 4, No 9
The prognosis for patients with pancreatic cancer is poor, even for patients with surgically resectable tumors. Gemcitabine (Gemzar) is the standard chemotherapy for advanced pancreatic cancer.
Read Article
Denosumab Improves Bone Metastasis–Free Survival in Patients with CRPC
In the Literature
November 2013, Vol 4, No 9
In a new exploratory analysis, researchers evaluated the relationship between PSA doubling time and BMFS, time to first bone metastasis, and OS in recipients of denosumab and placebo (Smith MR, et al.
J Clin Oncol
. 2013;31:3800-3806).
Read Article
Molecular Test Identifies Patients at Risk for Early and Late Breast Cancer Recurrence
In the Literature
October 2013, Vol 4, No 8
A new study compared the ability of 3 modalities—the new Breast Cancer Index (BCI) molecular test, the 21-gene recurrence score known as Oncotype DX, and the immunohistochemical (IHC4) prognostic model—to predict early and late disease recurrence in patients with ER-positive, node-negative breast cancer (Sgroi DC, et al.
Lancet Oncol
. 2013;14:1067-1076).
Read Article
PD-1 Inhibitor Lambrolizumab Is Safe, Shows Durable Responses in Patients with Advanced Melanoma
In the Literature
October 2013, Vol 4, No 8
Lambrolizumab (previously known as MK-3475) is a humanized monoclonal immunoglobulin G4 antibody that blocks the programmed death 1 (PD-1) receptor and reactivates an immune response to the cancer cells.
Read Article
Large-Scale Oncology Pathways Program Reduces Drug and Hospitalization Costs
In the Literature
October 2013, Vol 4, No 8
The cost of cancer care continues to rise, and especially the cost of cancer drugs. Since their introduction in the 1990s, clinical pathways have demonstrated an improvement in the quality of care, while lowering costs in numerous clinical settings.
Read Article
Ibrutinib Shows Durable Remissions in Patients with Relapsed CLL
In the Literature
September 2013, Vol 4, No 7
Treatment for chronic lymphocytic leukemia (CLL) has resulted in few cases of durable remissions. Bruton’s tyrosine kinase (BTK), an essential component of B-cell receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.
Read Article
Industry-Funded Studies Receive Greater Prominence at ASCO Meetings
In the Literature
September 2013, Vol 4, No 7
>The American Society of Clinical Oncology (ASCO) revised its policy on financial conflicts of interest (FCOIs) in 2005, establishing for the first time certain types of financial relationships for clinical trial principal investigators.
Read Article
Page 7 of 13
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma